Literature DB >> 11526391

Tolerogenic strategies to halt or prevent type 1 diabetes.

A Cooke1, J M Phillips, N M Parish.   

Abstract

A variety of therapeutic strategies have been developed to tolerize autoreactive T cells and prevent autoimmune pathology. In terms of type 1 diabetes, prevention strategies can inhibit the priming and expansion of autoreactive T cells; however, a cure for diabetes would require tolerance to be established in the presence of primed effector cells together with replacement of the destroyed beta cell mass. Replacement of beta cells could be accomplished by transplantation of islets or stem cells or through islet regeneration. We will focus here on tolerogenic strategies that have been used to prevent onset of type 1 diabetes and discuss the potential for a cure.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11526391     DOI: 10.1038/ni0901-810

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  13 in total

1.  Parameters influencing antigen-specific immunotherapy for Type 1 diabetes.

Authors:  Bo Wang; Roland Tisch
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

2.  Parameters influencing antigen-specific immunotherapy for type 1 diabetes.

Authors:  Bo Wang; Roland Tisch
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

3.  Antibody Binding to CD4 Induces Rac GTPase Activation and Alters T Cell Migration.

Authors:  Y Maurice Morillon; Elizabeth Chase Lessey-Morillon; Matthew Clark; Rui Zhang; Bo Wang; Keith Burridge; Roland Tisch
Journal:  J Immunol       Date:  2016-09-30       Impact factor: 5.422

4.  Autoimmune diabetes: ongoing development of immunological intervention strategies targeted directly against autoreactive T cells.

Authors:  Charles Sia
Journal:  Rev Diabet Stud       Date:  2004-05-10

5.  Programmed death-1 ligands-transfected dendritic cells loaded with glutamic acid decarboxylase 65 (GAD65) inhibit both the alloresponse and the GAD65-reactive lymphocyte response.

Authors:  F-R He; H-F Zhu; H Huang; Y D Dai; X Shen; M Wang; L Li; W Xing; G-X Shen
Journal:  Clin Exp Immunol       Date:  2007-11-15       Impact factor: 4.330

6.  Suppression of ongoing T cell-mediated autoimmunity by peptide-MHC class II dimer vaccination.

Authors:  Li Li; Zuoan Yi; Bo Wang; Roland Tisch
Journal:  J Immunol       Date:  2009-09-14       Impact factor: 5.422

7.  Interleukin-17-producing gammadelta+ T cells protect NOD mice from type 1 diabetes through a mechanism involving transforming growth factor-beta.

Authors:  Gencheng Han; Renxi Wang; Guojiang Chen; Jianan Wang; Ruonan Xu; Liyan Wang; Jiannan Feng; Xia Li; Renfeng Guo; Li Fu; Beifen Shen; Yan Li
Journal:  Immunology       Date:  2009-08-04       Impact factor: 7.397

8.  Type 1 diabetes development requires both CD4+ and CD8+ T cells and can be reversed by non-depleting antibodies targeting both T cell populations.

Authors:  Jenny M Phillips; Nicole M Parish; Tim Raine; Chris Bland; Yvonne Sawyer; Hugo De La Peña; Anne Cooke
Journal:  Rev Diabet Stud       Date:  2009-08-10

9.  Extrapancreatic insulin-producing cells in multiple organs in diabetes.

Authors:  Hideto Kojima; Mineko Fujimiya; Kazuhiro Matsumura; Tamio Nakahara; Manami Hara; Lawrence Chan
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-24       Impact factor: 11.205

Review 10.  New potential treatments for protection of pancreatic B-cell function in Type 1 diabetes.

Authors:  S Cernea; P Pozzilli
Journal:  Diabet Med       Date:  2008-11       Impact factor: 4.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.